Skip to content
Menu

Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsDowngradesPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.

Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.

Read at benzinga.com

← All stock news